-
1
-
-
14944385553
-
Global cancer statistics, 2002
-
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
-
(2005)
CA Cancer J Clin.
, vol.55
, pp. 74-108
-
-
Parkin, D.M.1
Bray, F.2
Ferlay, J.3
Pisani, P.4
-
2
-
-
0033874892
-
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
-
de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938-47.
-
(2000)
J Clin Oncol.
, vol.18
, pp. 2938-2947
-
-
de Gramont, A.1
Figer, A.2
Seymour, M.3
Homerin, M.4
Hmissi, A.5
Cassidy, J.6
-
3
-
-
0034727063
-
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer
-
Irinotecan Study Group
-
Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905-14.
-
(2000)
N Engl J Med.
, vol.343
, pp. 905-914
-
-
Saltz, L.B.1
Cox, J.V.2
Blanke, C.3
Rosen, L.S.4
Fehrenbacher, L.5
Moore, M.J.6
-
4
-
-
0023748414
-
Genetic alterations during colorectal-tumor development
-
Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525-32.
-
(1988)
N Engl J Med.
, vol.319
, pp. 525-532
-
-
Vogelstein, B.1
Fearon, E.R.2
Hamilton, S.R.3
Kern, S.E.4
Preisinger, A.C.5
Leppert, M.6
-
5
-
-
0028088897
-
Association of p53 mutations with short survival in colorectal cancer
-
Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, et al. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology. 1994;106:42-8.
-
(1994)
Gastroenterology.
, vol.106
, pp. 42-48
-
-
Hamelin, R.1
Laurent-Puig, P.2
Olschwang, S.3
Jego, N.4
Asselain, B.5
Remvikos, Y.6
-
6
-
-
0032521205
-
Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study
-
Ahnen DJ, Feigl P, Quan G, Fenoglio-Preiser C, Lovato LC, Bunn PA Jr, et al. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res. 1998;58:1149-58.
-
(1998)
Cancer Res.
, vol.58
, pp. 1149-1158
-
-
Ahnen, D.J.1
Feigl, P.2
Quan, G.3
Fenoglio-Preiser, C.4
Lovato, L.C.5
Bunn Jr, P.A.6
-
7
-
-
33947594129
-
Hyperactive Ras in developmental disorders and cancer
-
Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007;7:295-308.
-
(2007)
Nat Rev Cancer.
, vol.7
, pp. 295-308
-
-
Schubbert, S.1
Shannon, K.2
Bollag, G.3
-
8
-
-
42649145667
-
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
-
Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626-34.
-
(2008)
J Clin Oncol.
, vol.26
, pp. 1626-1634
-
-
Amado, R.G.1
Wolf, M.2
Peeters, M.3
Van Cutsem, E.4
Siena, S.5
Freeman, D.J.6
-
9
-
-
54949085398
-
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
-
Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757-65.
-
(2008)
N Engl J Med.
, vol.359
, pp. 1757-1765
-
-
Karapetis, C.S.1
Khambata-Ford, S.2
Jonker, D.J.3
O'Callaghan, C.J.4
Tu, D.5
Tebbutt, N.C.6
-
10
-
-
9144231228
-
Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature
-
Klump B, Nehls O, Okech T, Hsieh CJ, Gaco V, Gittinger FS, et al. Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature. Int J Colorectal Dis. 2004;19:23-42.
-
(2004)
Int J Colorectal Dis.
, vol.19
, pp. 23-42
-
-
Klump, B.1
Nehls, O.2
Okech, T.3
Hsieh, C.J.4
Gaco, V.5
Gittinger, F.S.6
-
11
-
-
75749102647
-
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial
-
Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010;28:466-74.
-
(2010)
J Clin Oncol.
, vol.28
, pp. 466-474
-
-
Roth, A.D.1
Tejpar, S.2
Delorenzi, M.3
Yan, P.4
Fiocca, R.5
Klingbiel, D.6
-
12
-
-
0033739215
-
Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study
-
Samowitz WS, Curtin K, Schaffer D, Robertson M, Leppert M, Slattery ML. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev. 2000;9:1193-7.
-
(2000)
Cancer Epidemiol Biomarkers Prev.
, vol.9
, pp. 1193-1197
-
-
Samowitz, W.S.1
Curtin, K.2
Schaffer, D.3
Robertson, M.4
Leppert, M.5
Slattery, M.L.6
-
13
-
-
21244450758
-
Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab
-
Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M, et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst. 2005;97:981-9.
-
(2005)
J Natl Cancer Inst.
, vol.97
, pp. 981-989
-
-
Ince, W.L.1
Jubb, A.M.2
Holden, S.N.3
Holmgren, E.B.4
Tobin, P.5
Sridhar, M.6
-
14
-
-
63849088630
-
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer
-
Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408-17.
-
(2009)
N Engl J Med.
, vol.360
, pp. 1408-1417
-
-
Van Cutsem, E.1
Kohne, C.H.2
Hitre, E.3
Zaluski, J.4
Chang Chien, C.R.5
Makhson, A.6
-
15
-
-
4944235005
-
Systematic review of genetic influences on the prognosis of colorectal cancer
-
Anwar S, Frayling IM, Scott NA, Carlson GL. Systematic review of genetic influences on the prognosis of colorectal cancer. Br J Surg. 2004;91:1275-91.
-
(2004)
Br J Surg.
, vol.91
, pp. 1275-1291
-
-
Anwar, S.1
Frayling, I.M.2
Scott, N.A.3
Carlson, G.L.4
-
16
-
-
33846595479
-
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer
-
Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24:5313-27.
-
(2006)
J Clin Oncol.
, vol.24
, pp. 5313-5327
-
-
Locker, G.Y.1
Hamilton, S.2
Harris, J.3
Jessup, J.M.4
Kemeny, N.5
Macdonald, J.S.6
-
18
-
-
24944525406
-
Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients
-
Westra JL, Schaapveld M, Hollema H, de Boer JP, Kraak MM, de Jong D, et al. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol. 2005;23:5635-43.
-
(2005)
J Clin Oncol.
, vol.23
, pp. 5635-5643
-
-
Westra, J.L.1
Schaapveld, M.2
Hollema, H.3
de Boer, J.P.4
Kraak, M.M.5
de Jong, D.6
-
19
-
-
0032490124
-
Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study
-
Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst. 1998;90:675-84.
-
(1998)
J Natl Cancer Inst.
, vol.90
, pp. 675-684
-
-
Andreyev, H.J.1
Norman, A.R.2
Cunningham, D.3
Oates, J.R.4
Clarke, P.A.5
-
20
-
-
0035444798
-
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study
-
Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer. 2001;85:692-6.
-
(2001)
Br J Cancer.
, vol.85
, pp. 692-696
-
-
Andreyev, H.J.1
Norman, A.R.2
Cunningham, D.3
Oates, J.4
Dix, B.R.5
Iacopetta, B.J.6
-
21
-
-
0042635802
-
Mutations of APC, K-ras, and p53 are associated with specific chromosomal aberrations in colorectal adenocarcinomas
-
Leslie A, Pratt NR, Gillespie K, Sales M, Kernohan NM, Smith G, et al. Mutations of APC, K-ras, and p53 are associated with specific chromosomal aberrations in colorectal adenocarcinomas. Cancer Res. 2003;63:4656-61.
-
(2003)
Cancer Res.
, vol.63
, pp. 4656-4661
-
-
Leslie, A.1
Pratt, N.R.2
Gillespie, K.3
Sales, M.4
Kernohan, N.M.5
Smith, G.6
-
22
-
-
0025634118
-
p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis
-
Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, Willson JK, et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res. 1990;50:7717-22.
-
(1990)
Cancer Res.
, vol.50
, pp. 7717-7722
-
-
Baker, S.J.1
Preisinger, A.C.2
Jessup, J.M.3
Paraskeva, C.4
Markowitz, S.5
Willson, J.K.6
-
23
-
-
0025312728
-
A genetic model for colorectal tumorigenesis
-
Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759-67.
-
(1990)
Cell.
, vol.61
, pp. 759-767
-
-
Fearon, E.R.1
Vogelstein, B.2
-
24
-
-
73349114941
-
KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial
-
Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol. 2009;27:5931-7.
-
(2009)
J Clin Oncol.
, vol.27
, pp. 5931-5937
-
-
Richman, S.D.1
Seymour, M.T.2
Chambers, P.3
Elliott, F.4
Daly, C.L.5
Meade, A.M.6
|